Why Medication Adherence Matters in Alcohol Recovery: Daily Naltrexone, Vivitrol and Longer-Acting Options
Prepared for medical review.
Review status: Pending.
When people compare medications for alcohol use disorder, they often ask which formulation is strongest. A more practical question may be: which treatment is most likely to remain in place when recovery becomes difficult?
Naltrexone is available in the United States as a daily oral medication and as a monthly extended-release injection. Longer-acting implant formulations are used or studied in some settings outside standard U.S. AUD care, but they are not FDA-approved in the United States for alcohol use disorder.
A medication cannot help on a day it is not taken
Daily oral naltrexone can be effective, but it requires a repeated decision: take today’s tablet. For many patients that is manageable. For others, adherence becomes difficult precisely when craving, stress or plans to drink are strongest.
This creates an important behavioural problem. The treatment decision can become part of the relapse decision.
A person may think: “I want to drink tonight, so I will skip the medication.”
Longer-acting formulations reduce how often that decision has to be reopened.
What does the evidence say about oral naltrexone versus Vivitrol?
A 2025 randomized clinical trial compared daily oral naltrexone with monthly extended-release injectable naltrexone in hospitalized patients with alcohol use disorder. Both groups had substantial reductions in heavy-drinking days, and the trial did not find a statistically significant difference in the primary drinking outcome.
However, adherence differed. High adherence was reported in 26.6% of the oral-naltrexone group compared with 40.7% of the extended-release injectable group. The odds of high medication adherence were significantly higher with the monthly injectable formulation.
That is an important distinction: a longer-acting formulation should not automatically be described as more effective pharmacologically, but it may make continued medication exposure easier to achieve.
Why continuity can matter on the hardest day
Recovery does not fail because every day is equally difficult. Often there are particular moments when risk rises: an argument, loneliness, social pressure, a celebration, a stressful week or an unexpected alcohol cue.
With a daily tablet, medication continuation is still a decision during that difficult period. With a monthly injection, the medication remains present between appointments. A still longer-acting delivery strategy is designed to extend that principle further.
The value of continuity may not be most visible on the easiest day of recovery. It may matter most when the patient has the strongest reason to abandon treatment.
How continuity can support counselling
Counselling works through repetition. A patient identifies triggers, tests alternative responses, learns from setbacks and gradually develops routines that do not depend on alcohol.
That process takes time. Sustained medication support may give the patient more uninterrupted opportunities to practise those responses while alcohol’s rewarding effects are being reduced.
This does not prove that longer medication exposure automatically makes psychotherapy more effective. The more defensible point is that treatment continuity can create a more stable period in which counselling and behavioural change can continue.
Why this matters for alcohol triggers
Alcohol cues can retain their power after detox. Research with extended-release naltrexone has found reduced brain reactivity to alcohol-related cues in regions involved in reward, emotion and learning.
If medication remains in place while the patient repeatedly experiences ordinary life without returning to drinking, triggers may gradually become less commanding. The patient can begin to learn that seeing alcohol, experiencing stress or reaching Friday evening does not have to produce the old behavioural outcome.
Daily, monthly and longer-acting delivery
| Form | How often treatment must be renewed | Main adherence consideration |
|---|---|---|
| Oral naltrexone | Usually daily | Requires repeated day-to-day adherence |
| Vivitrol / extended-release injectable naltrexone | Usually monthly | Removes daily pill decisions but requires return for injections |
| Longer-acting implant delivery | Designed for sustained release over months, depending on formulation | May reduce repeated dosing decisions further; AUD-specific implant evidence is more limited and U.S. FDA approval is absent |
Does longer acting mean better?
Not automatically. Patient preference, cost, access, side effects, medical suitability and follow-up all matter. The 2025 randomized trial did not show that monthly injectable naltrexone produced superior drinking outcomes to oral naltrexone over three months, even though adherence was higher.
For long-acting implants, the evidence base for alcohol use disorder remains substantially smaller than for oral or monthly injectable naltrexone. That limitation should be stated clearly.
The DeBinge continuity model
DeBinge is located in Nassau, The Bahamas. For medically suitable patients, its model is designed around medically managed withdrawal followed by long-acting naltrexone support and one year of counselling.
The proposed value is not that the naltrexone molecule becomes stronger. It is that the treatment plan is designed to remain present over a long recovery period without depending on a fresh medication decision every day.
For the broader alcohol-recovery pathway, read Alcohol Detox Is Only the Beginning: How Long-Acting Naltrexone May Support Recovery After Withdrawal.
Medical review
Prepared for medical review — Review status: Pending.
Medical reviewer: Dr Fergus Law, BSc, MBChB, FRCPsych, Consultant Psychiatrist specialising in substance misuse and addiction.
This article is educational and is not individual medical advice. Naltrexone is not suitable for everyone, including some people using opioids or with certain medical conditions. Treatment selection should be made with a qualified clinician.